Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 869-882

  Todorova, Margarita L ^a   Larroque, Anne Laure ^a   Dauphin Pierre, Sabine ^a   Fang, You Qiang ^a,b   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; QUINAZOLINE; XRCC1 PROTEIN;

ARTICLE; BREAST CANCER; BYSTANDER EFFECT; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DOWNSTREAM PROCESSING; ENZYME ASSAY; FLUORESCENCE; GENE TARGETING; HUMAN; HUMAN CELL; IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DANSYL COMPOUNDS; DNA DAMAGE; FLUORESCENT DYES; HUMANS; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; TRANSFECTION; TRIAZENES;

EID: 77950831852     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0673     Document Type: Article

References (48)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science (Washington, DC) 1987;235:177-182
2. Aaronson SA. Growth factors and cancer. Science 1991;254: 1146-1153
3. 3. Modjtahedi H, Dean C. The receptor for EGF and Its ligands: expression, prognostic value and target for therapy in cancer (review). Int J Oncol 1994;4:277-296 (Pubitemid 24039840)
4. 4. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16. (Pubitemid 43199589)
5. 5. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997; 3:2703-2707 (Pubitemid 28133130)
6. 6. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970 (Pubitemid 32963812)
7. 7. Albanell J, Gascon P. Small molecules with EGFR-TK inhibitor activity. Current Drug Targets 2005;6:259-274 (Pubitemid 40667794)
8. 8. Bos M, Mendelsohn J, Kim YM, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells In a receptor number-dependent manner. Clin Cancer Res 1997;3:2099-2106 (Pubitemid 27505138)
9. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-4848
10. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (lressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-1914.
11. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol Cancer Ther 2001 ;1:85-94.
12. 12. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1-21. (Pubitemid 36457237)
13. 13. Wlssner A, Brawner Floyd M, Rabindran SK, et al. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg Med Chem Lett 2002;12:2893-2897 (Pubitemid 35266757)
14. 14. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006;11:1047-1057 (Pubitemid 44788395)
15. 15. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004;64:5355-5362 (Pubitemid 39006556)
16. 16. Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs In radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007;83:238-248 (Pubitemid 46915540)
17. Katsoulas A, Rachid Z, McNamee JP, Williams C, Jean-Claude BJ. Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Mol Cancer Ther 2008;7:1033-1043
18. Matheson SL, McNamee J, Jean-Claude BJ. Design of a chimeric 3methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther 2001;296:832-840
19. Brahimi F, Matheson SL, Dudoult F, et al. Inhibition of epidermal growth factor receptor-mediated signaling by "combi-triazene" BJ2000, a new probe for combi-targeting postulates. J Pharmacol Exp Ther 2002;303:238-246
20. 20. Qiu Q, Dudoult F, Matheson SL, et al. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 2003;51:1-10. (Pubitemid 36057017)
21. 21. Qiu Q, Domarkas J, Banerjee R, et al. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anticancer Drugs 2007;18:171-177 (Pubitemid 44967427)
22. Qiu Q, Domarkas J, Banerjee R, et al. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res 2007;13:331-340
23. 23. Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple Inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem 2003;46:5546-5551 (Pubitemid 37490384)
24. Matheson SL, Brahimi F, Jean-Claude BJ. The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharmacol 2004;67:1131-1138
25. 25. Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate 2004;59: 13-21. (Pubitemid 38387839)
26. 26. Domarkas J, Dudouit F, Williams C, et al. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 2006;49:3544-3552 (Pubitemid 43902460)
27. 27. Matheson SL, McNamee JP, Wang T, et al. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther 2004;311:1163-1170 (Pubitemid 39612724)
28. 28. Matheson SL, Mzengeza S, Jean-Claude BJ. Synthesis of 1-[4-(mtolylamino)-6-quinazolinyl]-3-[14C]methyltriazene: a radiolabeled probe for the combi-targeting concept. J Labelled Comp Rad 2003;46:729-735 (Pubitemid 36890061)
29. 29. Broo K, Wei J, Marshall D, et al. Viral capsid mobility: a dynamic conduit for inactlvation. Proc Natl Acad Sci U S A 2001;98:2274-2277 (Pubitemid 32209472)
30. Larroque-Lombard AL, Todorova M, Golabl N, Williams C, JeanClaude B. Synthesis and differential uptake of fluorescence-labeled combi-molecule bu P-gp-preficient and deficient uterine sarcoma cells MES-SA and MES-SA/DX5. J Med Chem 2009, submitted.
31. 31. Skehan P, Storeng R, Scudlero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82: 1107-1112 (Pubitemid 20213250)
32. McNamee JP, McLean JR, Ferrarotto CL, Bellier PV. Comet assay: rapid processing of multiple samples. Mutat Res 2000;466:63-69
33. Olive PL, Banath JP. The comet assay: a method to measure DNA damage In individual cells. Nat Protocols 2006;1:23-29
34. Wojewodzka M, Buraczewska I, Kruszewski M. A modified neutral comet assay: elimination of lysis at high temperature and validation of the assay with anti-single-stranded DNA antibody. Mutat Res 2002;518:9-20.
35. Vindelov LL. Flow micrafluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei. Virchows Arch B Cell Pathol 1977;24: 227-242
36. Rachld Z, Brahimi F, Qlu Q, et al. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. J Med Chem 2007;50:2605-2608
37. Larroque A-L, Peori B, Williams C, et al. Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase. Chem Biol Drug Des 2008;71:374-379
38. Huang X, Halicka HD, Darzynkiewicz Z. Detection of histone H2AX phosphorylation on Ser-139 as an Indicator of DNA damage (DNA double-strand breaks). Curr Protoc Cytom 2004;Chapter 7: Unit 7 27.
39. Kinner A, Wu W, Staudt C, lliakis G. V-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008;36:5678-5694
40. Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-trlazenes". J Med Chem 2003;46: 4313-4321
41. Brahimi F, Rachid Z, Qiu Q, et al. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer 2004;112:484-491
42. Matheson SL, McNamee JP, Jean-Claude BJ. Differential responses of EGFRVAGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemoth Pharm 2003;51:11-20.
43. Banerjee R, McNamee JP, Jean-Claude BJ. The combi-targeting concept: selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing cancer cells by the complex combimolecule RB24 (NSC 741279). J Pharmacol Exp Ther 2009, Acceptable pending revision.
44. Lin S-Y, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biology 2001 ;3:802-808
45. Lo HW, Xia W, Wei Y, et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005;65: 338-348
46. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. Breast Cancer Res Treat 2006;95:211-218
47. Kim J, Jahng WJ, Di Vizio D, et al. The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Res 2007;67:9229-9237
48. Dittmann K, Mayer C, Kehlbach R, Rothmund MC, Peter Rodemann H. Radiation-Induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol 2009;92:379-382